Detalhe da pesquisa
1.
Exploring the impact of public health teams on alcohol premises licensing in England and Scotland (ExILEnS): procotol for a mixed methods natural experiment evaluation.
BMC Med Res Methodol
; 18(1): 123, 2018 11 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30400776
2.
Factors influencing public health engagement in alcohol licensing in England and Scotland including legal and structural differences: comparative interview analysis.
Public Health Res (Southampt)
; : 1-36, 2024 Feb 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38344914
3.
Public health engagement in alcohol licensing in England and Scotland: the ExILEnS mixed-method, natural experiment evaluation.
Public Health Res (Southampt)
; : 1-76, 2024 Feb 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38345369
4.
Measuring How Public Health Stakeholders Seek to Influence Alcohol Premises Licensing in England and Scotland: The Public Health Engagement In Alcohol Licensing (PHIAL) Measure.
J Stud Alcohol Drugs
; 84(2): 318-329, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36971718
5.
Impact of public health team engagement in alcohol licensing on health and crime outcomes in England and Scotland: A comparative timeseries study between 2012 and 2019.
Lancet Reg Health Eur
; 20: 100450, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-35799613
6.
Clinical, microbiological, and immunological characteristics in HIV-infected subjects at risk for disseminated Mycobacterium avium complex disease: an AACTG study.
AIDS Res Hum Retroviruses
; 21(8): 689-95, 2005 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-16131307
7.
A prospective, randomized trial examining the efficacy and safety of clarithromycin in combination with ethambutol, rifabutin, or both for the treatment of disseminated Mycobacterium avium complex disease in persons with acquired immunodeficiency syndrome.
Clin Infect Dis
; 37(9): 1234-43, 2003 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-14557969
8.
A multi-investigator/institutional DNA bank for AIDS-related human genetic studies: AACTG Protocol A5128.
HIV Clin Trials
; 4(5): 287-300, 2003.
Artigo
em Inglês
| MEDLINE | ID: mdl-14583845
9.
Daily low-dose subcutaneous interleukin-2 added to single- or dual-nucleoside therapy in HIV infection does not protect against CD4+ T-cell decline or improve other indices of immune function: results of a randomized controlled clinical trial (ACTG 248).
J Acquir Immune Defic Syndr
; 36(1): 576-87, 2004 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-15097300